Tregoning Kathleen — SEC Form 4 filings
SEC reporting owner CIK 1830764. 10 Form 4 filings on record with FilingPulse; latest filed 2026-07-08.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2023-12-21 to 2026-07-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 6,288 shares, $260,469 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 6,288 shares @ $41.42 ($260,469) in Cerevel Therapeutics Holdings, Inc., filed 2023-12-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Cerevel Therapeutics Holdings, Inc. (CERE) | See Remarks | 4 | — | 1 leg · 6,288 sh · $260,469 | 8 |
| Spero Therapeutics, Inc. (SPRO) | Director | 4 | — | — | 5 |
| COMPASS Pathways plc (CMPS) | Director | 1 | — | — | 1 |
| Kailera Therapeutics, Inc. (KLRA) | See Remarks | 1 | — | — | 1 |
Form 4 filings — Tregoning Kathleen
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-08 | 4 | Kailera Therapeutics, Inc. (KLRA) | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | COMPASS Pathways plc (CMPS) | Grant/award (A): 41,119 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-08-05 | 4 | Cerevel Therapeutics Holdings, Inc. (CERE) | Disposition to issuer (D): 10,666 · Disposition to issuer (D): 614,428 (derivative) · Disposition to issuer (D): 59,171 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2024-01-23 | 4 | Cerevel Therapeutics Holdings, Inc. (CERE) | Grant/award (A): 59,171 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Spero Therapeutics, Inc. (SPRO) | Grant/award (A): 35,604 (derivative) @ $1.12 | EDGAR |
| 2023-12-28 | 4 | Cerevel Therapeutics Holdings, Inc. (CERE) | Option exercise (M): 3,150 @ $10.05 · Option exercise (M): 3,150 (derivative) @ $0 | EDGAR |
| 2023-12-21 | 4 | Cerevel Therapeutics Holdings, Inc. (CERE) | Option exercise (M): 13,804 · Sale (S): 6,288 @ $41.42 · Option exercise (M): 13,804 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2023-12-20 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1830764 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →